Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Collagen-based biodegradable matrices for localized drug delivery More
Glutaminyl Cyclase (QC) is an enzyme responsible for pyroglutamate formation of beta amyloids peptides. Inhibition of QC activity can potentially act as an AD therapy or even prevention as plaque cores consist entirely of pyroglutamated beta amyloids More
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
Gastro Retentive Drug Delivery System More
The matrix consists of two polysaccharides, xanthan and locus More
Novel library of synthetic NGF agonists that bind in a highly specific manner the tropomyosin kinases (Trk) receptor. More
Method of inactivating prions by subjecting the substrate in which the prions are present to ultra high pressures. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Age-related disorders (other)
- Amyotrophic lateral sclerosis
- CNS (other)
- Neurodegenerative disorders
- Neurological
- Pain
- Psychiatric
- Subarachnoid hemorrhage
- Traumatic brain injury
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us